Legal & General Group
CTNM

Legal & General Group’s Contineum Therapeutics CTNM Stock Holding History

Legal & General Group’s Portfolio CTNM Stock Details CTNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,631
Closed -$25.3K – 3571
2025
Q1 		$25.3K Hold
3,631
– – ﹤0.01% 2861
2024
Q4 		$53.2K Buy
3,631
+1,544
+74% +$24.4K ﹤0.01% 2769
2024
Q3 		$39.9K Hold
2,087
– – ﹤0.01% 2829
2024
Q2 		$36.6K Buy
+2,087
New +$33.6K ﹤0.01% 2837

Other funds holding CTNM

JJ
Johnson & Johnson New Brunswick, New Jersey $652M AUM 198.07% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
RTM
Red Tree Management Redwood City, California $112M AUM 91.52% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return

Legal & General Group's CTNM Position: Q2 2025 in Review

Legal & General Group sold out of Contineum Therapeutics (CTNM) in Q2 2025, closing a stake of 3,631 shares — an estimated $25.3K sold.

Legal & General Group first reported a position in CTNM in Q2 2024 and held it in 4 quarters. The position peaked at $53.2K in Q4 2024. 70 funds tracked by Wall St. Rank hold CTNM as of Q2 2025.

  • Legal & General Group reported no remaining Contineum Therapeutics position as of Q2 2025 after selling out during the quarter.
  • Legal & General Group sold 3,631 Contineum Therapeutics shares in Q2 2025, an estimated $25.3K.
  • Legal & General Group first reported a position in Contineum Therapeutics in Q2 2024 and held it in 4 quarters.
  • Legal & General Group's Contineum Therapeutics position peaked at $53.2K in Q4 2024.
  • 70 funds tracked by Wall St. Rank held Contineum Therapeutics as of Q2 2025.

Based on Legal & General Group's 13F filing for Q2 2025, filed 12 Aug 2025.